Essex Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-30,720
| Closed | -$2.69M | – | 456 |
|
|
2020
Q4 | $2.69M | Buy |
30,720
+15,038
| +96% | +$1.19M | 0.33% | 97 |
|
|
2020
Q3 | $1.19M | Sell |
15,682
-29,530
| -65% | -$2.99M | 0.17% | 188 |
|
|
2020
Q2 | $5.58M | Buy |
45,212
+6,893
| +18% | +$685K | 0.91% | 17 |
|
|
2020
Q1 | $3.24M | Buy |
38,319
+492
| +1% | +$42.4K | 0.66% | 32 |
|
|
2019
Q4 | $3.2M | Buy |
37,827
+30,074
| +388% | +$2.27M | 0.39% | 69 |
|
|
2019
Q3 | $523K | Buy |
7,753
+1,119
| +17% | +$86.2K | 0.08% | 287 |
|
|
2019
Q2 | $568K | Sell |
6,634
-7,281
| -52% | -$623K | 0.08% | 294 |
|
|
2019
Q1 | $1.24M | Sell |
13,915
-61
| -0.4% | -$5.65K | 0.18% | 181 |
|
|
2018
Q4 | $1.19M | Sell |
13,976
-6,863
| -33% | -$653K | 0.19% | 167 |
|
|
2018
Q3 | $2.02M | Buy |
20,839
+8,406
| +68% | +$839K | 0.24% | 132 |
|
|
2018
Q2 | $1.17M | Sell |
12,433
-210
| -2% | -$18.4K | 0.15% | 206 |
|
|
2018
Q1 | $1.02M | Buy |
12,643
+859
| +7% | +$73.7K | 0.13% | 205 |
|
|
2017
Q4 | $1.05M | Buy |
11,784
+2,663
| +29% | +$232K | 0.14% | 210 |
|
|
2017
Q3 | $849K | Buy |
9,121
+1,618
| +22% | +$143K | 0.12% | 222 |
|
|
2017
Q2 | $681K | Sell |
7,503
-23
| -0.3% | -$2.09K | 0.1% | 234 |
|
|
2017
Q1 | $661K | Sell |
7,526
-949
| -11% | -$84.4K | 0.1% | 238 |
|
|
2016
Q4 | $702K | Sell |
8,475
-992
| -10% | -$85.3K | 0.12% | 211 |
|
|
2016
Q3 | $876K | Sell |
9,467
-5,944
| -39% | -$560K | 0.14% | 185 |
|
|
2016
Q2 | $1.2M | Buy |
15,411
+90
| +0.6% | +$7.65K | 0.2% | 118 |
|
|
2016
Q1 | $1.26M | Sell |
15,321
-203
| -1% | -$16.5K | 0.22% | 103 |
|
|
2015
Q4 | $1.63M | Sell |
15,524
-33,126
| -68% | -$3.46M | 0.25% | 94 |
|
|
2015
Q3 | $5.12M | Buy |
48,650
+18,675
| +62% | +$2.49M | 0.84% | 34 |
|
|
2015
Q2 | $4.1M | Sell |
29,975
-15,188
| -34% | -$1.88M | 0.62% | 42 |
|
|
2015
Q1 | $5.63M | Buy |
45,163
+6,095
| +16% | +$646K | 0.79% | 40 |
|
|
2014
Q4 | $3.53M | Sell |
39,068
-17
| -0% | -$1.41K | 0.51% | 54 |
|
|
2014
Q3 | $2.82M | Buy |
39,085
+7,788
| +25% | +$512K | 0.43% | 66 |
|
|
2014
Q2 | $1.95M | Sell |
31,297
-2,158
| -6% | -$130K | 0.29% | 112 |
|
|
2014
Q1 | $2.28M | Sell |
33,455
-1,417
| -4% | -$104K | 0.33% | 97 |
|
|
2013
Q4 | $2.45M | Buy |
34,872
+5,105
| +17% | +$347K | 0.35% | 80 |
|
|
2013
Q3 | $2.15M | Buy |
29,767
+15,278
| +105% | +$1.02M | 0.33% | 88 |
|
|
2013
Q2 | $808K | Buy |
+14,489
| New | +$903K | 0.14% | 174 |
|
Other funds holding BMRN
BBA
Essex Investment Management's BMRN Position: Q1 2021 in Review
Essex Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 30,720 shares — an estimated $2.69M sold.
Essex Investment Management first reported a position in BMRN in Q2 2013 and held it in 31 quarters. The position peaked at $5.63M in Q1 2015. 531 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.
- Essex Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
- Essex Investment Management sold 30,720 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $2.69M.
- Essex Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 31 quarters.
- Essex Investment Management's BioMarin Pharmaceuticals position peaked at $5.63M in Q1 2015.
- 531 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.
Based on Essex Investment Management's 13F filing for Q1 2021, filed 12 May 2021.